Newsroom

Recent News Releases

November 23, 2019 11/23/2019

Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68^th Annual Meeting

November 23, 2019 11/23/2019

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG^® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

November 14, 2019 11/14/2019

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

November 14, 2019 11/14/2019

TAKEDA ANNOUNCES LAUNCH OF EXCHANGE OFFER FOR ANY AND ALL OF ITS $1.250 BILLION 4.000% SENIOR NOTES DUE 2021, $1.500 BILLION 4.400% SENIOR NOTES DUE 2023 AND $1.750 BILLION 5.000% SENIOR NOTES DUE 2028

November 8, 2019 11/8/2019

New Analyses from the Phase 3 HELP Study^™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO^®(lanadelumab-flyo) Injection During Extended Study Treatment Period

SEE ALL NEWS AND RELEASES >

・For legacy Shire information, click here

Featured Topics

Takeda CEO Sees a Bright Future in Globalized Pharmaceuticals Market

LEARN MORE

Universal Health Coverage and the Power of People: United Nations General Assembly Side Event

LEARN MORE

Grand opening of new Dengue vaccine manufacturing plant in Singen, Germany

LEARN MORE

Raising standards in home parenteral nutrition

LEARN MORE

Understanding the impact of ADHD among adults

LEARN MORE

SEE ALL FEATURED TOPICS ARTICLES >

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.